Status:
COMPLETED
Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma
Lead Sponsor:
MacroGenics
Conditions:
Colorectal Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The primary goal of this Phase 1 study is to characterize the safety and tolerability of MGD007 and establish the maximum tolerated dose (MTD) and schedule of MGD007 administered to patients with meta...
Detailed Description
This is an open-label, multi-center, Phase 1 dose-escalation study to define a MTD, describe preliminarily safety, and to assess PK, immunogenicity, and potential anti-tumor activity of MGD007 in pati...
Eligibility Criteria
Inclusion
- For the dose escalation cohorts, histologically-proven metastatic colorectal adenocarcinoma that is refractory to 2 prior standard treatment regimens or standard treatment was declined.
- For the dose expansion cohorts, histologically-proven metastatic colorectal adenocarcinoma that is refractory to 1 prior standard treatment regimen or standard therapy was declined.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy of at least 12 weeks
- Measurable disease
- Intolerance to at least 2 prior standard therapy regimens
- Acceptable laboratory parameters
- Adult (≥18 years old)
Exclusion
- Known brain metastasis
- Any prior history of or suspected current autoimmune disorders (with the exception of vitiligo, resolved childhood atopic dermatitis, prior Grave's disease)
- Prior history of allogeneic bone marrow, stem-cell, or solid organ transplantation
- Prior treatment with checkpoint inhibitors and other immunotherapy treatments, including anti-LAG-3, anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibodies, if less than 5 half lives before study drug administration
- Prior history of Grade 3 or greater drug-related diarrhea/colitis during treatment with checkpoint inhibitors or other immunotherapy treatments.
- Treatment with any local or systemic anti-neoplastic therapy or any other investigational agent in the 4 weeks prior to study drug administration
- Require, at the time of study entry, treatment with steroids \> 10 mg/day of oral prednisone (or equivalent), except topical use, steroid inhaler, nasal spray or ophthalmic solution
- History of clinically significant cardiovascular disease, gastrointestinal disorder, or significant pulmonary compromise.
- Second primary malignancy that has not been in remission for greater than 3 years, with the exception of non-melanoma skin cancer, cervical carcinoma in situ,or squamous intraepithelial lesion on PAP smear, localized prostate cancer (Gleason score \<6), or resected melanoma in situ.
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 2 2018
Estimated Enrollment :
95 Patients enrolled
Trial Details
Trial ID
NCT02248805
Start Date
October 1 2014
End Date
July 2 2018
Last Update
February 8 2022
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale University, Yale Cancer Center
New Haven, Connecticut, United States
2
H. Lee Moffitt Cancer Center & Research Institute, Inc
Tampa, Florida, United States, 33612
3
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States, 21205
4
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114